Medicare Part D premium shock & IRA cost revision
Key Questions
When will Medicare begin covering GLP-1 weight loss drugs and what will the monthly cost be?
Coverage for GLP-1 drugs starts July 1, 2026, at a cost of $50 per month. This marks a significant new Medicare benefit with notable fiscal implications according to CMS data.
Who qualifies for the new GLP-1 Bridge program under Medicare?
The program has narrow eligibility limited to individuals with BMI of 35+ or 27+ with certain conditions. It excludes patients with diabetes or sleep apnea, offers no deductible credit, and serves as a temporary initiative for data collection.
What are the potential spending impacts of expanding Medicare GLP-1 coverage?
An AAF analysis indicates the program could grow into a multi-billion dollar initiative with 3.8 million eligible beneficiaries initially and expanding demographics. CMS reports identify GLP-1s as a primary driver of health spending growth, creating a political and fiscal cliff.
CMS ends Part D Premium Stabilization Demonstration for 2027, removing $3.6B subsidy that kept premiums low for 25M stand-alone enrollees. CBO revises IRA Part D redesign cost to $700B deficit increase over 10 years (was projected $129B savings). Premiums expected to rise $11-20/month; Oz claims <$10 impact but analysts warn of larger increases. This directly affects seniors' drug costs and adds to federal deficit. Ties to broader fiscal squeeze and Medicare market disruption.